Biznextindia : The phase-III data of Bharat Biotech’s indigenously developed COVID-19 vaccine has been approved by the Subject Expert Committee of the Drug Control General of India (DCGI). According to sources, Covaxin has shown 77.8 per cent efficacy in the phase-III clinical trial.
Last week, the Hyderabad based vaccine manufacturer had submitted its phase-III trial data before the DCGI. The phase-III trial was conducted on 25,800 subjects.
In January, DGCI had granted emergency use authorization to covaxin.